How Myqorzo’s Commercial Launch At Cytokinetics (CYTK) Has Changed Its Investment Story
Cytokinetics has entered a new phase as a commercial-stage biotech following past FDA approval of Myqorzo for symptomatic obstructive hypertrophic cardiomyopathy and its subsequent European...
